Viewing Study NCT05322317



Ignite Creation Date: 2024-05-06 @ 5:29 PM
Last Modification Date: 2024-10-26 @ 2:29 PM
Study NCT ID: NCT05322317
Status: COMPLETED
Last Update Posted: 2022-11-18
First Post: 2022-03-10

Brief Title: Advance Care Planning ACP in Primary Care for Dementia
Sponsor: Oregon Health and Science University
Organization: Oregon Health and Science University

Study Overview

Official Title: Testing Critical Components for a Trial of Advance Care Planning in Primary Care for Dementia
Status: COMPLETED
Status Verified Date: 2022-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ADVANCE-PC
Brief Summary: ADVANCE-PC Aligning Dementia adVANce Care planning Education in Primary Care is a communications and implementation support intervention that builds on existing ACP programs understanding of dementia and clinical expertise to provide training and technical assistance tailored to the needs of primary care clinicians and clinics that are often over-burdened and under-resourced For this pilot we will recruit six primary care clinics to test the ADVANCE-PC delivered using remote technology ECHO The pilot will include conducting one ECHO cycle and assessing the feasibility and acceptability of the program content and this mode of delivery Aim 1 and testing pragmatic outcome assessment for the intervention Aim 2
Detailed Description: Aim 1 To assess the feasibility acceptability and content utility of the ECHO program among the clinicians in the participating primary care clinics Data will be collected to assess successful program implementation and participant engagement We will document outreach efforts reporting why clinics decline to participate and as well as the initial motivations of those who agree Data will be collected from participating clinicians a pre-training questionnaire about their prior experience with ACP and dementia feedback at the end of each session and a longer questionnaire at the end of the training that measures intentions to engage in ACP their understanding of dementia their confidence in engaging patients and families in ACP and what barriers they expect to encounter Attendance will be documented and ECHO sessions will be recorded so participation and trainee engagement can be assessed At the end of the follow-up period clinicians will participate in interviews focused on barriers to and facilitators of ACP in the context of dementia Feasibility and acceptability of this intervention will be evaluated using descriptive and qualitative analyses of these data

Aim 2 To pilot test the ascertainment of outcomes for the ADVANCE-PC program in the 3-month period when trained clinicians are attempting to conduct ACP routinely in their clinics The primary outcome will be the proportion of patients with dementia andor their care partners seen by participating clinicians who are engaged in ACP To pilot test pragmatic assessment of this outcome we will work with clinics to determine how the number of patients with dementia seen in a defined period the denominator and number who are engaged in ACP the numerator can be efficiently identified in by each clinic using their electronic health record EHR We will collect information on EHR functionality and current dementia and ACP documentation during Months 1-3 and integrate support for documentation and measurement into the training Our secondary outcomes are clinician confidence intentions and behavior related to ACP These will be evaluated during the ECHO program using questionnaires modeled after data collection activities routinely used by clinics for quality improvement and formally measured and analyzed using research questionnaires pre and post completion of the ECHO program and a semi structured interview at the end of the follow-up period

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None